The secondary efficacy end-points were differences in daily mean : ( i ) voiding frequency at 4 and 8weeks ; ( ii ) urgency frequency ; ( iii ) urgency incontinence frequency ; ( iv ) incontinence frequency ; ( v ) nocturia frequency ; and ( vi ) quality of life score .